Abstract
Phage therapy is an effective and safe way to treat infectious diseases caused by various types of bacteria, including mastitis in cows. However, the number of in vivo studies on phages to treat cattle with staphylococcal mastitis is relatively low. This study aimed to evaluate the therapeutic efficacy of the bacteriophage drug Fagomast in treating cows with staphylococcal mastitis in its clinical manifestation and compare the results with commercial antimastitis drugs based on antibiotics. For this purpose, groups of cows with signs of clinical mastitis caused by S. aureus were formed. Cows of the experimental group were administered intracisternal bacteriophage drug Fagomast, and animals of the control group were used drugs based on antibiotics. Cows were considered healthy in the disappearance of clinical manifestations of the disease and adverse reactions in mastidin test. According to the research results, it is established that the effectiveness of therapy in the clinical form of staphylococcal mastitis with the use of intra-tank antimastitis drugs based on antibiotics is from 66.7 to 100 %, and with the help of bacteriophage drug Fagomast – 71.4 %. The period during which the rejection of milk during the treatment of clinical mastitis drug Fagomast was 1.5 times less than in treating such mastitis drugs containing antibiotics. Thus, the drug Fagomast is generally not inferior to traditional treatment methods with antibiotics. Therefore, the use of Fagomast in treating staphylococcal mastitis is relevant and promising.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.